Inventor · disambiguated record
Qilong Wu
Also filed as: WU QILONG
24 granted patents·12 pending applications·322 citations·filing 2014–2025
96Inventor score
Top patents by PatentIndex Score
36 records- 0197US10174095B2Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptorNOVARTIS AG·Filed 2015·Granted Jan 8, 2019·41 cites·50 claims
- 0297US9815901B2Treatment of cancer using a CD123 chimeric antigen receptorBROGDON JENNIFER·Filed 2015·Granted Nov 14, 2017·94 cites·40 claims
- 0397US9777061B2Treatment of cancer using a CD33 chimeric antigen receptorNOVARTIS AG·Filed 2015·Granted Oct 3, 2017·85 cites·24 claims
- 0495US11084880B2Anti-BCMA chimeric antigen receptorNOVARTIS AG·Filed 2018·Granted Aug 10, 2021·15 cites·24 claims
- 0594US10287354B2Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2014·Granted May 14, 2019·29 cites·63 claims
- 0693US10654914B2Polyomavirus neutralizing antibodiesNOVARTIS AG·Filed 2018·Granted May 19, 2020·5 cites·21 claims
- 0793US10640569B2Human mesothelin chimeric antigen receptors and uses thereofNOVARTIS AG·Filed 2014·Granted May 5, 2020·15 cites·49 claims
- 0892US10577417B2Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapyNOVARTIS AG·Filed 2015·Granted Mar 3, 2020·10 cites·33 claims
- 0991US11639378B2Polyomavirus neutralizing antibodiesNOVARTIS AG·Filed 2021·Granted May 2, 2023·1 cites·19 claims
- 1089US10435460B2Polyomavirus neutralizing antibodiesNOVARTIS AG·Filed 2017·Granted Oct 8, 2019·5 cites·26 claims
- 1189US2025051423A1Polyomavirus neutralizing antibodiesNOVARTIS AG·Filed 2024·Application pending·0 cites
- 1288US11161894B2Polyomavirus neutralizing antibodiesNOVARTIS AG·Filed 2019·Granted Nov 2, 2021·2 cites·21 claims
- 1388US10450366B2Polyomavirus neutralizing antibodiesNOVARTIS AG·Filed 2016·Granted Oct 22, 2019·5 cites·21 claims
- 1486US12077571B2Polyomavirus neutralizing antibodiesNOVARTIS AG·Filed 2023·Granted Sep 3, 2024·0 cites·20 claims
- 1585US10568947B2Treatment of cancer using a CLL-1 chimeric antigen receptorNOVARTIS AG·Filed 2015·Granted Feb 25, 2020·6 cites·38 claims
- 1685US2025011461A1Human mesothelin chimeric antigen receptors and uses thereofNOVARTIS AG·Filed 2024·Application pending·0 cites
- 1784US9862760B2Polyomavirus neutralizing antibodiesABEND JOHANNA·Filed 2016·Granted Jan 9, 2018·6 cites·26 claims
- 1883US11578130B2Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2018·Granted Feb 14, 2023·1 cites·30 claims
- 1983US10703819B2Treatment of cancer using a CD123 chimeric antigen receptorNOVARTIS AG·Filed 2017·Granted Jul 7, 2020·1 cites·33 claims
- 2082US10851166B2Treatment of cancer using a CD33 chimeric antigen receptorNOVARTIS AG·Filed 2017·Granted Dec 1, 2020·1 cites·22 claims
- 2182US2024294662A1Human mesothelin chimeric antigen receptors and uses thereofNOVARTIS AG·Filed 2024·Application pending·0 cites
- 2279US2023220090A1Treatment of cancer using a cd123 chimeric antigen receptorNOVARTIS AG·Filed 2022·Application pending·0 cites
- 2379US2025353916A1Treatment of cancer using a cd33 chimeric antigen receptorNOVARTIS AG·Filed 2025·Application pending·0 cites
- 2478US2024317850A1Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapyNOVARTIS AG·Filed 2024·Application pending·0 cites
- 2572US2023026049A1Regulatable chimeric antigen receptorNOVARTIS AG·Filed 2022·Application pending·0 cites
- 2670US12214037B2Treatment of cancer using humanized anti-BCMA chimeric antigen receptorUNIV PENNSYLVANIA·Filed 2021·Granted Feb 4, 2025·0 cites·16 claims
- 2770US11591404B2Treatment of cancer using a CD123 chimeric antigen receptorNOVARTIS AG·Filed 2020·Granted Feb 28, 2023·0 cites·33 claims
- 2870US2023052970A1Phosphoglycerate kinase 1 (pgk) promoters and methods of use for expressing chimeric antigen receptorNOVARTIS AG·Filed 2022·Application pending·0 cites
- 2969US12338287B2Treatment of cancer using a CD33 chimeric antigen receptorNOVARTIS AG·Filed 2020·Granted Jun 24, 2025·0 cites·24 claims
- 3067US11999794B2Human mesothelin chimeric antigen receptors and uses thereofNOVARTIS AG·Filed 2020·Granted Jun 4, 2024·0 cites·21 claims
- 3165US2020215171A1Treatment of cancer using a cll-1 chimeric antigen receptorNOVARTIS AG·Filed 2019·Application pending·0 cites
- 3264US2020339651A1Methods for b cell preconditioning in car therapyNOVARTIS AG·Filed 2019·Application pending·0 cites
- 3362US11981731B2Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapyNOVARTIS AG·Filed 2020·Granted May 14, 2024·0 cites·17 claims
- 3454US11459390B2Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptorNOVARTIS AG·Filed 2016·Granted Oct 4, 2022·0 cites·21 claims
- 3551US2018334490A1Methods for b cell preconditioning in car therapyBROGDON JENNIFER·Filed 2015·Application pending·0 cites
- 3639US2021198368A1Multispecific molecules targeting cll-1NOVARTIS AG·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Qilong Wu files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →